Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FBIO
Previous Symbol
CUSIP21976U10
Phone781-652-4500
Debt
Debt-to-Equity Ratio0.76
Current Ratio2.25
Quick Ratio2.24
Price-To-Earnings
Trailing P/E Ratio-0.81
Forward P/E Ratio-0.59
P/E GrowthN/A
Sales & Book Value
Annual Sales$187.58 million
Price / Sales0.40
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book0.55
Profitability
EPS (Most Recent Fiscal Year)($1.61)
Net Income$-66,870,000.00
Net Margins-30.52%
Return on Equity-68.16%
Return on Assets-28.65%
Miscellaneous
Employees68
Outstanding Shares56,680,000
Market Cap$69.72 million
OptionableOptionable
Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions
What is Fortress Biotech's stock symbol?
Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
How were Fortress Biotech's earnings last quarter?
Fortress Biotech (NASDAQ:FBIO) announced its earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.18. The biopharmaceutical company earned $63.69 million during the quarter, compared to analyst estimates of $64.88 million. Fortress Biotech had a negative net margin of 30.52% and a negative return on equity of 68.16%. View Fortress Biotech's Earnings History.
When is Fortress Biotech's next earnings date?
What price target have analysts set for FBIO?
3 analysts have issued 12 month price objectives for Fortress Biotech's shares. Their predictions range from $10.00 to $11.00. On average, they expect Fortress Biotech's share price to reach $10.6667 in the next twelve months. This suggests a possible upside of 714.2% from the stock's current price. View Analyst Price Targets for Fortress Biotech.
What is the consensus analysts' recommendation for Fortress Biotech?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.
Has Fortress Biotech been receiving favorable news coverage?
News articles about FBIO stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fortress Biotech earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Fortress Biotech's key competitors?
Some companies that are related to Fortress Biotech include Syros Pharmaceuticals (SYRS), BioDelivery Sciences International (BDSI), Avid Bioservices (CDMO), CELYAD SA/ADR (CYAD), Affimed (AFMD), Neptune Wellness Solutions (NEPT), Evelo Biosciences (EVLO), Arbutus Biopharma (ABUS), Aduro BioTech (ADRO), Magenta Therapeutics (MGTA), Acer Therapeutics (ACER), Tocagen (TOCA), Axovant Sciences (AXON), Synlogic (SYBX) and Unum Therapeutics (UMRX).
Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 63)
- Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 61)
- Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 52)
- Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 56)
- Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 64)
Who are Fortress Biotech's major shareholders?
Fortress Biotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.70%), Opus Point Partners Management LLC (0.43%), JPMorgan Chase & Co. (0.37%), JPMorgan Chase & Co. (0.37%) and Cpwm LLC (0.31%). Company insiders that own Fortress Biotech stock include George Avgerinos and Lindsay A Md Rosenwald. View Institutional Ownership Trends for Fortress Biotech.
Which institutional investors are buying Fortress Biotech stock?
FBIO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Opus Point Partners Management LLC, Cpwm LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. View Insider Buying and Selling for Fortress Biotech.
How do I buy shares of Fortress Biotech?
Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fortress Biotech's stock price today?
One share of FBIO stock can currently be purchased for approximately $1.31.
How big of a company is Fortress Biotech?
Fortress Biotech has a market capitalization of $69.72 million and generates $187.58 million in revenue each year. The biopharmaceutical company earns $-66,870,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.
What is Fortress Biotech's official website?
How can I contact Fortress Biotech?
Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
